Denosumab: A review of its use in postmenopausal women with osteoporosis

Drugs and Aging

Volumn 31, Issue 7, 2014, Pages 555-576

  Scott, Lesley J ^a  

^a Adis ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PRALIA; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, HUMAN;

ASIAN; BONE DENSITY; BONE TURNOVER; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMUR NECK; FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; LUMBAR SPINE; POSTMARKETING SURVEILLANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SPINE FRACTURE; ANTAGONISTS AND INHIBITORS; ECONOMICS; FEMALE; METABOLISM; OSTEOPOROSIS, POSTMENOPAUSAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND;

EID: 84903777690     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0191-3     Document Type: Review

References (87)

1. World Health Organization. Prevention and management of osteoporosis: WHO Technical Report series no. 92. 2003. http://whqlibdoc.who.int/trs/who-trs- 92pdf. Accessed 6 Jan 2014.
2. Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause. 2010;17(1):25-54.
3. National Institute for Health and Clinical Excellence. Osteoporosis: assessing the risk of fragility fracture. NICE clinical guideline 146. 2012. http://guidance.nice.org.uk/CG146/NICEGuidance/pdf/English. Accessed 6 Jan 2014.
4. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16(Suppl 2):3-7.
5. Chitre M, Shechter D, Grauer A. Denosumab for treatment of postmenopausal osteoporosis. Am J Health Syst Pharm. 2011;68(15):1409-18.
6. Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82.
7. Reginster J-Y. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs. 2011;71(1):65-78.
8. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19(7):1059-66. (Pubitemid 41110556)
9. European Medicines Agency. Prolia 60 mg solution in a prefilled syringe: summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR---Product-Information/human/001120/WC500093526.pdf. Accessed 26 Nov 2013.
10. Amgen Manufacturing Limited. Prolia® (denosumab) injection, for subcutaneous use: US prescribing information. 2013. http://pi.amgen.com/united- states/prolia/prolia-pi.pdf. Accessed 26 Nov 2013.
11. Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011;50(12):793-807.
12. Kumagai Y, Hasunuma T, Padhi D. A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. Bone. 2011;49:1101-7.
13. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22(12):1832-41. (Pubitemid 351229299)
14. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-31. (Pubitemid 43290920)
15. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222-9.
16. Miller PD, Wagman RB, Peacock M, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab. 2011;96(2):394-402.
17. McClung MR, Lewiecki EM, Geller ML, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013;24(1):227-35.
18. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum appears in N Engl J Med. 2009;361(19):1914]. N Engl J Med. 2009;361(8):756-65.
19. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694-701.
20. Ferrari S, Adachi JD, Zapalowski C, et al. Further reduction in the nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the FREEDOM extension [abstract no. 1017]. American Society for Bone and Mineral Research Annual Meeting; 4-7 Oct 2013; Baltimore.
21. Papapoulos S, Lippuner K, Roux C, et al. Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extension [abstract no. LB-M026]. American Society for Bone and Mineral Research Annual Meeting; 4-7 Oct 2013; Baltimore.
22. Bone HG, Chapurlat R, Brandi M-L, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Met. 2013;98(11):4483-92.
23. Roux C, Lippuner K, Bone HG, et al. Denosumab treatment of postmenopausal women with osteoporosis for 7 years: clinical fracture results from the first 4 years of the FREEDOM extension [abstract no. OP0250]. Ann Rheum Dis. 2013;72(Suppl 3):137.
24. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149-57. (Pubitemid 351831529)
25. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972-80.
26. Zebaze RM, Libanati C, McClung MR, et al. Denosumab reduces hip cortical porosity in women with osteoporosis [abstract no. 1065]. American Society for Bone and Mineral Research Annual Meeting; 4-7 Oct 2013; Baltimore.
27. Bolognese MA, Teglbjaerg CS, Zanchetta JR, et al. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom. 2013;16(2):147-53.
28. McClung MR, Boonen S, Törring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res. 2012;27(1):211-8.
29. Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96(6):1727-36.
30. Brown JP, Roux C, Törring O, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J Bone Miner Res. 2013;28(4):746-52.
31. McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. 2012;27(7):1480-6.
32. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829-35.
33. Simon JA, Recknor C, Moffett AH Jr, et al. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause. 2013;20(2):130-7.
34. McClung MR, Zanchetta JR, Høiseth A, et al. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. J Clin Densitom. 2013;16(2):250-6.
35. Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010;25(10):2256-65.
36. Keaveny TM, McClung MR, Genant HK, et al. Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res. 2014;29(1):158-65.
37. Genant HK, Keaveny TM, Zapalowski C, et al. Cortical bone parameters at the hip in response to denosumab vs placebo and the clinical relevance of these changes in postmenopausal women with osteoporosis <75 and ≥75 years old [abstract no. SAO400]. American Society for Bone and Mineral Research Annual Meeting; 4-7 Oct 2013; Baltimore.
38. Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):530-7.
39. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72-81.
40. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153-61.
41. Recknor C, Czerwinski E, Bone HG, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013;121(6):1291-9.
42. Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone Miner. 2014;58:48-54.
43. Nakamura T, Matsumoto T, Sugimoto T, et al. Effects of denosumab on fracture risk in Japanese patients with osteoporosis: results of 2-year data from the denosumab fracture intervention randomized placebo controlled trial (DIRECT) [abstract no. 1098]. J Bone Miner Res. 2012;27(Suppl 1):S32.
44. Silverman S, Viswanathan HN, Yang YC, et al. Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial. Osteoporos Int. 2012;23:1361-9.
45. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25(8):1886-94.
46. Zebaze RM, Libanati C, Austin M, et al. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014;59:173-9.
47. Kendler DL, Bessette L, Hill CD, et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int. 2010;21(5):837-46.
48. Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317-26.
49. Kendler DL, McClung MR, Freemantle N, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int. 2011;22(6):1725-35.
50. Kendler DL, Macarios D, Lillestol MJ, et al. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the denosumab adherence preference satisfaction study. Menopause. 2014;21(1):25-32.
51. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50-6.
52. Tsai J, Uihlein A, Zhu Y, et al. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density and microarchitecture: the DATA-HRpQCT Study [abstract no. SA0372]. American Society for Bone and Mineral Research Annual Meeting; 4-7 Oct 2013; Baltimore.
53. Koh J-M, Oh H-J, Park IH, et al. Efficacy and safety results from a six month double-blind study comparing 60 mg denosumab (DMAb) and placebo in Korean postmenopausal women with osteoporosis [abstract no. SAO386]. American Society for Bone and Mineral Research Annual Meeting; 4-7 Oct 2013; Baltimore.
54. Nakamura T, Matsumoto T, Sugimoto T, et al. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int. 2012;23(3):1131-40.
55. Hiligsmann M, Ethgen O, Bruyère O, et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health. 2009;12(5):687-96.
56. Parthan A, Kruse M, Yurgin N, et al. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy. 2013;11:485-97.
57. Barbosa E, Machado M, Araujo G, et al. Cost-effectiveness of denosumab in preventing osteoporotic fractures in postmenopausal women from the private healthcare setting perspective in Brazil [abstract no. PMS41]. In: 15th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research; 3-7 Nov 2012; Berlin.
58. Chau D, Becker DL, Coombes ME, et al. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. J Med Econ. 2012;15(Suppl 1):3-14.
59. Ström O, Jönsson B, Kanis JA. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis. Osteoporos Int. 2013;24(4):1491-502.
60. Ström O, Borgström F, Kleman M, et al. FRAX® and its applications in health economics: cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone. 2010;47(2):430-7.
61. Watts NB, Roux C, Modlin JF, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int. 2012;23(1):327-37.
62. Geller M, Wagman RB, Ho PR, et al. Early findings from Prolia® post-marketing safety surveillance for atypical femoral fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis [abstract]. International Osteoporosis Federation World Congress on Osteoporosis and 13th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; 2-5 Apr 2014; Seville.
63. Diz P, Lopez-Cedrun L, Arenaz J, et al. Denosumab-related osteonecrosis of the jaw. J Am Dental Assoc. 2012;143(9):981-4.
64. Rachner TD, Platzbecker U, Felsenberg D, et al. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. Mayo Clin Proc. 2013;88(4):418-9.
65. Neuprez A, Coste S, Rompen E, et al. Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporos Int. 2014;25:393-5.
66. Hadji P, Papaioannou NA, Gielen E, et al. 12-Month persistence with denosumab (DMab) in women with postmenopausal osteoporosis (PMO): interim results of a 24-month prospective observational study in Germany, Austria, Greece and Belgium [abstract]. International Osteoporosis Federation World Congress on Osteoporosis and 13th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; 2-5 Apr 2014; Seville.
67. Thompson RN, Armstrong CL, Heyburn G. Bilateral atypical femoral fractures in a patient prescribed denosumab: a case report. Bone. 2014;61(1):44-7.
68. Drampolos E, Skarpas G, Barbounakis N, et al. Atypical femoral fractures bilaterally in a patient receiving denosumab: a case report. Acta Orthop. 2014;85(1):3-5.
69. Villiers J, Clark DW, Jeswani T, et al. An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol. 2013. doi:10.1155/2013/249872.
70. Adami S, Libanati C, Boonen S, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am. 2012;94(23):2113-9.
71. Samelson EJ, Miller PD, Christiansen C, et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res. 2014;29(2):450-7.
72. Daiichi-Sankyo Company. Daiichi Sankyo receives approval in Japan for manufacturing and marketing of Pralia®, a new treatment for osteoporosis. 2013. http://www.daiichisankyo.com/media-investors/media-relations/press- releases/detail/005123.html. Accessed 26 Nov 2013.
73. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. 2013. http://nof.org/files/nof/public/content/ resource/913/files/580.pdf. Accessed 21 Jan 2014.
74. Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in potmenopausal women. Osteoporos Int. 2013;24(1):23-57.
75. Miller P, Derman RJ. What is the best balance of benefits and risks among anti-resorptive agents for postmenopausal osteoporosis? Osteoporos Int. 2010;21(11):1793-802.
76. Silverman S, Christiansen C. Individualizing osteoporosis therapy. Osteoporos Int. 2012;23:797-809.
77. Diab DL, Watts NB. Postmenopausal osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2013;20:501-9.
78. Lewiecki EM, Miller PD, Harris ST, et al. Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. J Clin Densitom. 2013. doi:10.1016/j.jocd.2013.09. 018.
79. Diel IJ, Bergner R, Grötz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol. 2007;5(10):475-82.
80. Karlsson L, Lundkvist J, Psachoulia E, et al. Literature review and meta-analysis of persistence with oral bisphosphonates [abstract]. International Osteoporosis Federation World Congress on Osteoporosis and 13th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; 2-5 Apr 2014; Seville.
81. Hadji P, Intorcia M, Psachoulia E, et al. GRAND 3: the German retrospective cohort analysis on non-adherence in osteoporotic patients: persistence analysis of female patients treated with denosumab [abstract]. International Osteoporosis Federation World Congress on Osteoporosis and 13th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; 2-5 Apr 2014; Seville.
82. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-22. (Pubitemid 44175011)
83. Badamgarav E, Fitzpatrick LA. A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc. 2006;81(8):1009-12. (Pubitemid 44175010)
84. Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122 Suppl l:S3-13.
85. Hadji P, Claus V, Ziller V, et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23(1):223-31.
86. Qi W-X, Tang L-A, He A-N, et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014. doi:10.1007/s10147-013-0561-6.
87. Xue F, Ma H, Stehman-Breen C, et al. Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis. Pharmacoepidemiol Drug Saf. 2013;22:1107-14.